register

News & Trends - MedTech & Diagnostics

MicroPort Orthopedics’ titanium modular necks pose risk of fracture

Health Industry Hub | August 31, 2020 |

MedTech News: MicroPort Orthopedics, in consultation with the TGA, has initiated a hazard alert for all lot numbers of Profemur Long and Extra-Long Titanium Modular Necks due to the risk of the implant fracturing.

Profemur Titanium Modular Necks are a component used in some hip replacement procedures.

A component with the potential to fracture cannot be detected during surgery or by visual inspection or any other diagnostic technique. While fractures are rare, should one occur the patient may experience sudden pain, instability and difficulty walking/performing common tasks.

The total global fracture rate of Long and Extra-Long Profemur Titanium Modular Necks is currently 0.552 per cent. The fracture rate in Australia is currently 0.997 per cent with six fractures reported in Australia from 2002 to 2019.

Profemur Titanium Long and Extra-Long Modular Necks have not been used in Australia since 2012 and were cancelled from the Australian Register of Therapeutic Goods (ARTG) in 2015.

No other MicroPort Orthopedics products are included in this hazard alert.

The fractured components occur when stresses produced at the modular neck/stem taper interface in heavy and/or highly active patients in whom predominantly longer offsets can exceed the fatigue strength of the modular neck.

MicroPort Orthopedics has written to all surgeons who have received supplies of the affected components to advise them of the hazard alert.

Surgeons are advised that MicroPort Orthopedics does not recommend prophylactic revision surgery, but does advise continuing to monitor the relevant patients according to the standard follow-up protocol.

The affected lots are:

  • PHA01204 Profemur neck NEUTRAL – LONG
  • PHA01214 Profemur neck A/R VAR/VAL 2 – LONG
  • PHA01224 Profemur neck A/R VAR/VAL 1 – LONG
  • PHA01234 Profemur neck 8DG A/R – LONG
  • PHA01244 Profemur neck 15DG A/R – LONG
  • PHA01254 Profemur neck 8DG VAR/VAL – LONG
  • PHA01264 Profemur neck 15DG VAR/VAL – LONG
  • PHA01206 Profemur neck NEUTRAL – EXTRA LONG
  • PHA01236 Profemur neck 8DG A/R – EXTRA LONG
  • PHA01256 Profemur neck 8DG VAR/VAL – EXTRA LONG

News & Trends - Biotechnology

CSL reshapes R&D while bracing for U.S. tariffs

CSL reshapes R&D while bracing for U.S. tariffs

Health Industry Hub | July 11, 2025 |

Australia’s largest biotech company CSL is streamlining its R&D operations to enhance efficiency amidst a rapidly evolving global landscape. The […]

More


News & Trends - MedTech & Diagnostics

Australia joins Medtronic trial in fight against resistant hypertension

Australia joins Medtronic trial in fight against resistant hypertension

Health Industry Hub | July 11, 2025 |

Medtronic has launched an international clinical trial across Australia, the United States, and Europe to evaluate the feasibility of multi-organ […]

More


News & Trends - MedTech & Diagnostics

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban

Health Industry Hub | July 11, 2025 |

Medibank has become the first Australian health insurer to pay towards pharmacogenetic testing (PGx) for eligible customers on Extras cover. […]

More


News & Trends - Pharmaceuticals

Global pledge shifts visibility and action for patients with advanced breast cancer

Global pledge shifts visibility and action for patients with advanced breast cancer

Health Industry Hub | July 11, 2025 |

Three breast cancer organisations have united internationally to demand that people living with metastatic breast cancer (MBC) are no longer […]

More


This content is copyright protected. Please subscribe to gain access.